Hofseth Biocare ASA: ANNOUNCES THE USE OF A VIRTUAL PLATFORM TO RECRUIT COVID-19 PATIENTS IN CANADA TO THE PHASE 2 TRIAL. WILL ALSO ASSESS THE IMPACT OF OMEGO ON HOSPITALISED PATIENTS WITH SEVERE FORMS OF COVID-19 IN MEXICO AND BRAZIL Reference is made to the stock exchange notice on 26 May 2020 and 30 June 2020. Hofseth BioCare ASA (“HBC”) announces that the first part of its accelerated phase 2 trial of CARDIO™ soft gels for the...

Hofseth Biocare ASA: HBC har startet protokollutvikling for en akselerert klinisk fase 2-studie med OmeGo® for å redusere akutt lungesvikt og behovet for kunstig åndedrett hos COVID-19 pasienter Hofseth BioCare ASA (“HBC”) forbereder en protokoll med KGK Science til Health Canada for å gjennomføre en fase 2 klinisk studie som skal vurdere OmeGo® i form av HBCs ferdigprodukt CARDIO...

Hofseth Biocare ASA: HBC has begun protocol development for its accelerated Phase 2 clinical trial with OmeGo® to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration in COVID-19 patients Hofseth BioCare ASA (“HBC”) is preparing an investigational protocol with KGK Science into Health Canada to conduct a Phase 2 clinical trial assessing OmeGo® in the form of our branded product CARDIO...